MedTrace Logo

Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19

NCT04380714 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2020-12-29

No results posted yet for this study

Summary

The SARS-CoV 2 pandemic started in China in December 2019, then reached France on January 24, 2020.

On March 14, France moved into phase 3 of the epidemic threshold with the implementation of containment measures on March 17 Measures were put in place by N.Belloubet (French Minister of Justice) from March 17, including suspension of visiting rooms and activities in detention.

Containment provides boredom and isolation with many potential consequences: sleep disturbance, anxiety, PTSD, depression, suicide, addictive behavior and violence.

However,prisoners have a higher prevalence of substance use disorders than the general population.

What will have been the impact of the confinement on the consumption of psychoactive substances by prisoners at the Villeneuve Les Maguelone prison.

* Anonymous questionnaire from the start
* Collection of socio-demographic data
* Collection of consumption data before and during containment
* Collection of monitoring data

Conditions

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Aurélie Mieuset, PhD · University Hospitals of Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-05-30
Completion
2020-08-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04380714 on ClinicalTrials.gov